drugset / Trial / NCT00924534

A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes

NCT00924534

Phase 2 Completed 61 enrolled Abbott Products Quintiles, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes

Timeline

Start
2009-12
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SLV337 Unknown 400 mg
Subject SLV337 Unknown 800 mg
Subject SLV337 Unknown 1400 mg